Intravenous Infusions Plc, a pharmaceutical company, manufactures and markets intravenous infusions and small volume injections for therapeutic purposes in Ghana and the West African sub-region.
Price History & Performance
|Historical stock prices|
|Current Share Price||GH₵0.05|
|52 Week High||GH₵0|
|52 Week Low||GH₵0|
|1 Month Change||0%|
|3 Month Change||n/a|
|1 Year Change||0%|
|3 Year Change||-44.44%|
|5 Year Change||-44.44%|
|Change since IPO||-37.50%|
Recent News & Updates
|IIL||GH Pharmaceuticals||GH Market|
Return vs Industry: IIL underperformed the GH Pharmaceuticals industry which returned 87.5% over the past year.
Return vs Market: IIL underperformed the GH Market which returned 67.3% over the past year.
Stable Share Price: Insufficient data to determine IIL's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine IIL's volatility change over the past year.
About the Company
Intravenous Infusions Plc, a pharmaceutical company, manufactures and markets intravenous infusions and small volume injections for therapeutic purposes in Ghana and the West African sub-region. The company offers intravenous infusion therapy products, including sodium chloride, dextrose, dextrose saline, poly-saline lactate, and special solutions; pethidine, magnesium sulphate, and quinine small volume injections; administrative sets; and other products, such as metronidazole injection, alcohol rub sanitizers, gel rub, and rubbing/disinfecting. The company was incorporated in 1969 and is based in Koforidua, Ghana.
Intravenous Infusions Fundamentals Summary
|IIL fundamental statistics|
Is IIL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IIL income statement (TTM)|
|Cost of Revenue||GH₵10.49m|
Last Reported Earnings
Dec 31, 2020
Next Earnings Date
|Earnings per share (EPS)||0.0053|
|Net Profit Margin||7.02%|
How did IIL perform over the long term?See historical performance and comparison
5.8%Current Dividend Yield
Is Intravenous Infusions undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: IIL (GHS0.05) is trading above our estimate of fair value (GHS0.03)
Significantly Below Fair Value: IIL is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IIL's PE Ratio (9.5x) is in line with the African Pharmaceuticals industry average.
PE vs Market: IIL is poor value based on its PE Ratio (9.5x) compared to the GH market (5.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IIL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IIL is good value based on its PB Ratio (0.8x) compared to the XF Pharmaceuticals industry average (1.6x).
How is Intravenous Infusions forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Intravenous Infusions has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Intravenous Infusions performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IIL has a high level of non-cash earnings.
Growing Profit Margin: IIL's current net profit margins (7%) are lower than last year (8.1%).
Past Earnings Growth Analysis
Earnings Trend: IIL has become profitable over the past 5 years, growing earnings by 30% per year.
Accelerating Growth: IIL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: IIL had negative earnings growth (-22.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10%).
Return on Equity
High ROE: IIL's Return on Equity (8.1%) is considered low.
How is Intravenous Infusions's financial position?
Financial Position Analysis
Short Term Liabilities: IIL's short term assets (GHS23.5M) exceed its short term liabilities (GHS10.9M).
Long Term Liabilities: IIL's short term assets (GHS23.5M) exceed its long term liabilities (GHS8.5M).
Debt to Equity History and Analysis
Debt Level: IIL's debt to equity ratio (66.5%) is considered high.
Reducing Debt: IIL's debt to equity ratio has increased from 26.3% to 66.5% over the past 5 years.
Debt Coverage: IIL's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: IIL's interest payments on its debt are well covered by EBIT (5x coverage).
What is Intravenous Infusions's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: IIL's dividend (5.82%) is higher than the bottom 25% of dividend payers in the GH market (4.71%).
High Dividend: IIL's dividend (5.82%) is low compared to the top 25% of dividend payers in the GH market (8.17%).
Stability and Growth of Payments
Stable Dividend: IIL has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: IIL has only been paying a dividend for 2 years, and since then payments have fallen.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (55%), IIL's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Soalihu Moukhtar (50 yo)
Mr. Soalihu M. Moukhtar serves as Managing Director and Director at Intravenous Infusions Plc since September 2020 and served as its Ag. Managing Director since 2020 until 2020. He served as Head of Financ...
Experienced Management: IIL's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Experienced Board: IIL's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6%.
Intravenous Infusions Plc's employee growth, exchange listings and data sources
- Name: Intravenous Infusions Plc
- Ticker: IIL
- Exchange: GHSE
- Founded: 1969
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: GH₵13.720m
- Shares outstanding: 274.41m
- Website: https://www.iil.com.gh
- Intravenous Infusions Plc
- Plot 4/7, Blk L Effiduase
- PO Box KF 63
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/17 17:04|
|End of Day Share Price||2021/10/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.